Filing Flows › Vivos Therapeutics (VVOS) › Q2 2026 › vs Q1 2026
Vivos Therapeutics (VVOS) Q2 2026 vs Q1 2026 (quarter over quarter)
Vivos Therapeutics's revenue rose $12K (+0.2%) from $5.1M in Q1 2026 to $5.2M in Q2 2026. The biggest changes: Service +$189K (+5%); Product −$176K (-12%).
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Sleep Testing Services | $2.4M | $2.3M | $96K | +4% |
| Treatment Centers | $767K | $892K | −$125K | -14% |
| Tooth Positioners | $715K | $1.0M | −$303K | -30% |
| Appliances | $640K | $422K | $218K | +52% |
| Myofunctional Therapy Services | $337K | $125K | $212K | +170% |
| Sponsorship Seminar Other | $161K | $205K | −$44K | -21% |
| Billing Intelligence Services | $129K | $145K | −$16K | -11% |
| VIP | $12K | $37K | −$25K | -68% |
| Service | $3.8M | $3.6M | $189K | +5% |
| Product | $1.4M | $1.5M | −$176K | -12% |
| Revenue | $5.2M | $5.1M | $12K | +0.2% |
| Net loss | $5.5M | $7.8M | −$2.2M | -29% |
| Costs & expenses | $10.7M | $12.9M | −$2.2M | -17% |
| Operating costs | $10.0M | $11.8M | −$1.8M | -15% |
| Interest & other, net | $698K | $1.1M | −$438K | -39% |
| Cost of revenue | $2.2M | $2.1M | $118K | +6% |
| Sales & marketing | $155K | $249K | −$94K | -38% |
| General & admin | $7.1M | $9.0M | −$1.9M | -21% |
| Other operating costs | $510K | $454K | $56K | +12% |
| Operating cash sources | $5.5M | $7.8M | −$2.2M | -29% |
| Depreciation & amortization | $510K | $454K | $56K | +12% |
| Share-based compensation | $50K | $151K | −$101K | -67% |
| Working capital & other | $1.8M | $1.1M | $679K | +60% |
| Cash used in operations | $3.1M | $6.0M | −$2.9M | -48% |
| Net loss absorbed | $5.5M | $7.8M | −$2.2M | -29% |
Questions
How much did Vivos Therapeutics's revenue grow quarter over quarter in Q2 2026?
Vivos Therapeutics's revenue rose $12K (+0.2%) from $5.1M in Q1 2026 to $5.2M in Q2 2026.
What drove Vivos Therapeutics's revenue change in Q2 2026?
Service +$189K (+5%); Product −$176K (-12%).